Jia Jie Biomedical Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Wen-Fang Hsieh

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	Veri yok

Son yönetim güncellemeleri

Recent updates

How Much Did Jia Jie Biomedical's(GTSM:4109) Shareholders Earn From Share Price Movements Over The Last Five Years?

Jan 21

CEO

Wen-Fang Hsieh

less than a year

Görev süresi

Wen-Fang Hsieh is Chief Executive Officer of Jia Jie Biomedical Co. Ltd. from January 16, 2024.

Jia Jie Biomedical Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Jia Jie Biomedical Co., Ltd Announces Resignation of Chen, He-Shun as Supervisor of Titan Insurance Broker Co., Ltd, Effective August 19, 2024

Jia Jie Biomedical Co., Ltd., Annual General Meeting, Jun 19, 2024

Jia Jie Biomedical Co., Ltd. Appoints Hsieh, Wen-Fang as CEO

Recent updates

Third quarter 2024 earnings released

Jia Jie Biomedical Co., Ltd. to Report Q3, 2024 Results on Nov 12, 2024

Upcoming dividend of NT$0.50 per share

Second quarter 2024 earnings released: EPS: NT$2.17 (vs NT$0.14 loss in 2Q 2023)

New major risk - Share price stability

Jia Jie Biomedical Co., Ltd Announces Resignation of Chen, He-Shun as Supervisor of Titan Insurance Broker Co., Ltd, Effective August 19, 2024

Jia Jie Biomedical Co., Ltd. to Report Q2, 2024 Results on Aug 08, 2024

Investor sentiment improves as stock rises 19%

Investor sentiment improves as stock rises 16%

First quarter 2024 earnings released: EPS: NT$0.14 (vs NT$0.26 loss in 1Q 2023)

Investor sentiment deteriorates as stock falls 16%

Jia Jie Biomedical Co., Ltd. to Report Q1, 2024 Results on May 07, 2024

Jia Jie Biomedical Co., Ltd. to Report Q1, 2024 Results on May 07, 2024

New minor risk - Shareholder dilution

Jia Jie Biomedical Co., Ltd., Annual General Meeting, Jun 19, 2024

Jia Jie Biomedical Co., Ltd. Appoints Hsieh, Wen-Fang as CEO

New minor risk - Share price stability

Jia Jie Biomedical Co., Ltd. announced that it expects to receive TWD 130.7 million in funding

Third quarter 2023 earnings released: EPS: NT$0.21 (vs NT$0.027 in 3Q 2022)

Second quarter 2023 earnings released: NT$0.14 loss per share (vs NT$0.016 loss in 2Q 2022)

Third quarter 2022 earnings released: EPS: NT$0.03 (vs NT$0.006 in 3Q 2021)

Third quarter 2022 earnings released: EPS: NT$0.03 (vs NT$0.006 in 3Q 2021)

Second quarter 2022 earnings released: NT$0.02 loss per share (vs NT$0.005 loss in 2Q 2021)

First quarter 2022 earnings released: NT$0.02 loss per share (vs NT$0.034 loss in 1Q 2021)

Full year 2021 earnings released: EPS: NT$0.06 (vs NT$0.46 loss in FY 2020)

Third quarter 2021 earnings released: EPS NT$0.01 (vs NT$0.073 in 3Q 2020)

Second quarter 2021 earnings released: NT$0.003 loss per share (vs NT$0.36 loss in 2Q 2020)

First quarter 2021 earnings released: NT$0.03 loss per share (vs NT$0.037 loss in 1Q 2020)

Full year 2020 earnings released: NT$0.46 loss per share (vs NT$0.35 loss in FY 2019)

New 90-day low: NT$15.95

New 90-day low: NT$16.40

How Much Did Jia Jie Biomedical's(GTSM:4109) Shareholders Earn From Share Price Movements Over The Last Five Years?

New 90-day high: NT$18.45

Third quarter 2020 earnings released: EPS NT$0.07

New 90-day high: NT$17.50

First half earnings released

New 90-day low - NT$14.90

CEO

Görev süresi